Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, has opened its Center of Excellence for Biologics and Cell and Gene Therapy in the heart of Research Triangle Park (RTP), North Carolina.

Spanning 50,000 square feet, the new center is Solvias’ flagship North American site for large molecule analytical services designed to accelerate the development and commercialization of innovative biologics. The facility will bring approximately 200 new jobs to the Raleigh-Durham area over the next three years and is being rolled out in two phases:

• Phase 1: A 20,000-square-foot space for cGMP release testing—featuring cell-based potency and molecular assays—operational immediately.
• Phase 2: An additional 30,000 square feet expected to open in July 2025, offering expanded capabilities for stability testing and advanced biophysical characterization.

Equipped with analytical instrumentation, laboratory automation, and advanced digital management systems, the new center offers comprehensive GMP testing for cell and gene therapies, monoclonal antibodies (mAbs), and other biologics, from preclinical stages to commercial release.

“This Center of Excellence in RTP is a milestone in Solvias’ global growth journey,” said Archie Cullen, CEO of Solvias. “Combining our team’s expertise with advanced technology, we aim to set a new benchmark for delivering high-quality, reliable analytical support. It’s an honor to partner with our clients in bringing groundbreaking therapies to patients worldwide.”

Solvias’ new center expands its global footprint to six centers of excellence and marks the company’s second site in North America.